Treatment with lanifibranor, a pan PPAR agonist in patients with severe active NASH led to lowering of a histologically assessed score of NASH activity, also in a subset of diabetic patients [16]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.